Human Tumor Antigens and Cancer Immunotherapy

Abstract EN

With the recent developments of adoptive T cell therapies and the use of new monoclonal antibodies against the immune checkpoints, immunotherapy is at a turning point.

Key players for the success of these therapies are the cytolytic T lymphocytes, which are a subset of T cells able to recognize and kill tumor cells.

Here, I review the nature of the antigenic peptides recognized by these T cells and the processes involved in their presentation.

I discuss the importance of understanding how each antigenic peptide is processed in the context of immunotherapy and vaccine delivery.